RxDoctor Payments DataLook up a doctor →

Eden Miller, DO

Family Medicine · Bend, ORNPI 1114997988

Payments from drug & device makers

$1,700,515in general payments, 2019–2025

Across 2,993 payments — averaging $568.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$635K
  • Abbott$298K
  • Novo Nordisk$291K
  • Insulet Corporation$148K
  • Boehringer Ingelheim$73K
  • Bayer$71K
  • plus $186K from 45 others

What the payments were for

  • Consulting fees$234,50114%
  • Speaking & faculty fees$1,224,85474%
  • Travel & lodging$153,4259%
  • Food & beverage$42,1673%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,700,515 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.

See all family medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$47,103
Medicare patients
108
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide233$269,507
JardianceEmpagliflozin180$219,295
OzempicSemaglutide138$175,848
TrulicityDulaglutide60$85,728
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/754$65,634
EliquisApixaban24$28,301
Humalog Kwikpen U-200Insulin Lispro18$26,987
Tresiba Flextouch U-200Insulin Degludec26$25,004
Tresiba Flextouch U-100Insulin Degludec35$24,297
JanuviaSitagliptin Phosphate23$19,817
Soliqua 100-33Insulin Glargine/Lixisenatide18$19,294
NovologInsulin Aspart62$17,090
Fiasp FlextouchInsulin Aspart (Niacinamide)18$13,265
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$12,412
KerendiaFinerenone13$11,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog$634,952$371,161329 claims
Boehringer IngelheimJardiance, Synjardy Xr$72,549$229,098197 claims
Novo NordiskOzempic, Novolog$290,900$192,938200 claims
PfizerEliquis$327$28,30124 claims
MerckJanuvia$5,260$19,81723 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$26,583$19,29418 claims
BayerKerendia$70,544$11,71513 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$108$10,54920 claims
AbbVieSynthroid$258$52515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.

Other family medicine in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →